Contemporary pharmacotherapies involving nitric oxide, prostacyclin, and endothelin receptor signaling pathways

Nicholas M. Furiasse, Jonathan D. Rich*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


The progressive disorder of pulmonary arterial hypertension (PAH) is marked by a complex pathobiology of pulmonary vascular remodeling, including dysregulated cellular proliferation and inappropriate local and systemic inflammatory responses. The various approved therapies for PAH currently target some of these pathways and have collectively led to improvements in symptoms and overall survival. Specifically, each approved therapy targets one of either the prostacyclin, endothelin, or nitric oxide pathways, respectively. Moreover, each of these broad classes of drugs and the individual drugs within each class has been studied in a variety of contexts and each has unique characteristics relevant to the clinician caring for the PAH patient. In this chapter we provide an in depth review of the currently available pharmacotherapies targeting the prostacyclin, endothelin, and nitric oxide signaling pathways.

Original languageEnglish (US)
Title of host publicationPulmonary Hypertension
Subtitle of host publicationBasic Science to Clinical Medicine
PublisherSpringer International Publishing
Number of pages14
ISBN (Electronic)9783319235943
ISBN (Print)9783319235936
StatePublished - Jan 1 2015


  • Endothelin receptor antagonists
  • Pathophysiology
  • Phosphodiesterase-5-Inhibitors
  • Prostacyclins
  • Pulmonary arterial hypertension
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Contemporary pharmacotherapies involving nitric oxide, prostacyclin, and endothelin receptor signaling pathways'. Together they form a unique fingerprint.

Cite this